TRESK Channel Activation Reduces Migraine Pain by Blocking CGRP Release From Nerve Endings
The TRESK channel activator cloxyquin reduced migraine-like pain, CGRP release, and mast cell degranulation in rat models, with effects abolished by a specific TRESK inhibitor and synergistic with sumatriptan.
Quick Facts
What This Study Found
TRESK activation by cloxyquin reduced CGRP release, allodynia, and mast cell degranulation in migraine models, with all effects specifically blocked by TRESK inhibitor A2764 and synergistic with sumatriptan ex vivo.
Key Numbers
Multiple dose levels of cloxyquin tested; compared against sumatriptan (established migraine drug) and A2764 (TRESK inhibitor) in various combinations.
How They Did This
In vivo nitroglycerin-induced migraine model and ex vivo meningeal, trigeminal ganglion, and brainstem preparations in rats, testing TRESK activator cloxyquin, TRESK inhibitor A2764, and sumatriptan alone and in combinations.
Why This Research Matters
CGRP-targeting drugs have revolutionized migraine treatment, but not all patients respond. TRESK channels offer an upstream mechanism to reduce CGRP release, potentially helping patients who don't benefit from current CGRP-blocking therapies.
The Bigger Picture
TRESK channels represent a new therapeutic target upstream of CGRP in the migraine cascade. Activating these channels could provide an alternative or complementary approach to the current wave of CGRP-targeting antibodies and antagonists.
What This Study Doesn't Tell Us
Animal model results may not fully translate to human migraine; cloxyquin is not a clinically approved drug; synergistic effect seen ex vivo but not in vivo; specific TRESK activators for human use need development; single migraine model tested.
Questions This Raises
- ?Can selective TRESK activators be developed for safe human use?
- ?Would TRESK activation benefit migraine patients who don't respond to CGRP-targeting drugs?
- ?Why did the synergistic effect with sumatriptan appear ex vivo but not in vivo?
Trust & Context
- Key Stat:
- TRESK → CGRP↓ TRESK channel activation reduces CGRP release across multiple migraine-relevant brain and nerve structures
- Evidence Grade:
- Preliminary preclinical evidence with strong mechanistic validation (specific inhibitor controls), but no human data available.
- Study Age:
- Published in 2024, representing emerging research into novel ion channel targets for migraine treatment.
- Original Title:
- TRESK channel activation ameliorates migraine-like pain via modulation of CGRP release from the trigeminovascular system and meningeal mast cells in experimental migraine models.
- Published In:
- Life sciences, 357, 123091 (2024)
- Database ID:
- RPEP-09398
Evidence Hierarchy
Frequently Asked Questions
What are TRESK channels and how do they relate to migraines?
TRESK channels are potassium channels found in migraine-relevant nerve cells. When activated, they reduce the release of CGRP — the same pain-promoting peptide targeted by newer migraine drugs. This offers a new way to reduce CGRP activity from a different angle.
Could this lead to new migraine medications?
Potentially — the study showed TRESK activators can reduce migraine-like symptoms in rats and even work synergistically with sumatriptan. The next step is developing selective TRESK activators safe for human use.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09398APA
Torun, Ibrahim Ethem; Kilinc, Yasemin Baranoglu; Kilinc, Erkan; Töre, Fatma. (2024). TRESK channel activation ameliorates migraine-like pain via modulation of CGRP release from the trigeminovascular system and meningeal mast cells in experimental migraine models.. Life sciences, 357, 123091. https://doi.org/10.1016/j.lfs.2024.123091
MLA
Torun, Ibrahim Ethem, et al. "TRESK channel activation ameliorates migraine-like pain via modulation of CGRP release from the trigeminovascular system and meningeal mast cells in experimental migraine models.." Life sciences, 2024. https://doi.org/10.1016/j.lfs.2024.123091
RethinkPeptides
RethinkPeptides Research Database. "TRESK channel activation ameliorates migraine-like pain via ..." RPEP-09398. Retrieved from https://rethinkpeptides.com/research/torun-2024-tresk-channel-activation-ameliorates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.